CTI BIOPHARMA CORP company info

CIK 891293
IRS Number 911533912
State of incorporation DE
Business address 3101 WESTERN AVENUE
SUITE 800
SEATTLE
WA
98121
Mail address 3101 WESTERN AVENUE
SUITE 800
SEATTLE
WA
98121

Short summary

CTI BIOPHARMA CORP is a Washington company, with head office located at 3101 Western Avenue Seattle, Washington 98121. In 2019 the company owned a total of 58.58 million USD worth of assets, including 49.67 million USD worth of current assets. 2017 was the year when the company amassed the most assets.

CTI BIOPHARMA CORP Income Statement

Name [in Millions USD]200820092010201120122013201420152016201720182019Trends
Cost of Goods and Services Sold 0.360.88
Selling, General and Administrative Expense 57.7348.0438.2938.2442.2956.2453.9645.3131.4421.18
Research and development 30.1827.0334.90
Operating Income (Loss) -81.56-74.76-62.19-101.50-41.53-86.23-116.67-49.16-39.52-32.90
Interest expense 4.812.330.870.061.031.952.102.611.871.21
Other Nonoperating Income (Expense) -0.48-0.55-0.89-0.90-0.48-0.094.30
Net income -95.40-82.64-62.36-101.37-42.74-93.37-119.42-52.01-40.67-29.32

CTI BIOPHARMA CORP Balance Sheet

Name [in Millions USD]200820092010201120122013201420152016201720182019Trends
Cash and cash equivalents 11.9864.5338.8914.7628.5733.1854.8676.7174.7465.3735.3634.92
Accounts Receivable, Net, Current 0.780.610.880.560.480
Inventories 3.335.023.612.631.5100
Property, Plant and Equipment, Gross 15.5417.2316.1316.3111.7711.839.939.68
Accumulated Depreciation, Depletion and Amortization, Property, Plant, and Equipment 11.9410.4510.6611.668.058.817.567.88
Goodwill 17.060
Other Assets, Noncurrent 6.069.278.177.328.015.455.325.335.458.097.53
Total assets 94.5856.5838.3449.2355.2673.4697.6386.33102.5966.2458.58
Current assets 67.9442.7921.8035.6142.2563.8688.9078.3695.0656.6349.67
Accounts payable 6.197.3113.5211.346.4411.1814.034.013.721.102.97
Total current liabilities 64.6536.7833.3822.5823.7933.1040.7536.4622.2417.9827.92
Long-term Debt, Excluding Current Maturities 7.739.4048.8015.387.0111.676.860
Long-term Debt 8.079.27
Deferred Revenue, Noncurrent 0.241.401.430.780.610
Total liabilities 77.7140.2239.8336.1340.6888.9960.8847.4138.9431.2632.39
Common Stock, Value, Issued 1,539.511,545.321,753.470.060.060.06
Retained Earnings (Accumulated Deficit) -1,526.92-1,667.23-1,790.83-1,867.46-1,936.10-2,036.89-2,114.77-2,169.11-2,210.78-2,245.33-2,300
Accumulated Other Comprehensive Income (Loss), Net of Tax -7.67-8.84-7.92-7.95-8.44-6.89-6.45-6.44-9.90-10.62-10.66

CTI BIOPHARMA CORP Cash Flow

Name [in Millions USD]200820092010201120122013201420152016201720182019Trends
Net income -95.40-82.64-62.36-101.37-42.74-93.37-119.42-52.01-40.67-29.32
Depreciation and amortization 1.771.842.412.351.571.1010.830.700.59
Accounts receivable -0.990.231.98-1.560.16-0.40-0.00
Inventories 1.593.25-0.310.40-0.57-1.120
Accounts payable -1.48-1.40-0.313.12-5.771.454.37-3.03-4.731.87
Deferred revenue 2.64-0.03-0.92-1.070.79
Net Cash Provided by (Used in) Operating Activities -88.19-63.13-60.46-62.78-35.83-95.20-76.68-39.30-39.82
Payments to Acquire Property, Plant, and Equipment 1.482.012.702.941.660.330.080.140.050.03
Net Cash Provided by (Used in) Investing Activities 21.84-2.28-2.67-20.70-1.53-0.08-0.14-0.04-30.49
Net Cash Provided by (Used in) Investing Activities, Continuing Operations -20.70-1.53-0.54-0.08-0.14
Proceeds from Issuance of Long-term Debt 14.50
Stock Issued During Period, Value, Share-based Compensation, Net of Forfeitures 24.9417.055.027.949.0720.2014.8313.325.756.37
Stock Issued During Period, Value, Share-based Compensation, Net of Forfeitures 24.9417.055.027.949.0720.2014.8313.325.756.37
Proceeds from Issuance of Common Stock 0015.150064.17
Payments for Repurchase of Common Stock 6.390.930.41
Net Cash Provided by (Used in) Financing Activities 94.7849.7287.0087.2258.97152.02-7.3738.9863.49
Cash and Cash Equivalents, Period Increase (Decrease) 27.74-15.1624.403.3821.20-0.7157.25-84.18